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Endotoxemia causes several hematological dysfunctions, including platelet degranulation or dis-
seminated intravascular coagulation, which lead to thrombotic and hemorrhagic events. Here,
we tested the hypothesis that bacterial lipopolysaccharide (LPS)-stimulated leukocytes con-
tribute to platelet aggregative dysfunction, and this function is attenuated by antioxidants. Platelet-
rich plasma (PRP) was prepared from whole blood of normal and endotoxemic rats. The ability
of platelet aggregation was measured by an aggregometer. LPS (50–100 μg/mL) was incubated
with PRP, whole blood and PRP with polymorphonuclear leukocytes (PMNs) for 30 minutes, 
60 minutes and 90 minutes, and platelet aggregation was detected. LPS-induced platelet aggregative
dysfunction was undetectable in intact PRP which was isolated from normal whole blood, whereas
it was detected in PRP isolated from endotoxemic rats and LPS-treated whole blood. Moreover, the
effect of LPS-induced platelet aggregative dysfunction on intact PRP was observed when the PMNs
were added. LPS-induced platelet aggregative dysfunction was significantly attenuated by catalase
alone and in combination with NG-nitro-L-arginine methyl ester, but not by NG-nitro-L-arginine
methyl ester alone. These results indicate that LPS-stimulated PMNs modulate platelet aggregation
during LPS treatment and the effects are reversed by antioxidants. PMNs serve as an approach to
understand LPS-induced platelet aggregative dysfunction during endotoxemia. During this process,
the generation of reactive oxygen species, hydrogen peroxide especially, from LPS-stimulated
PMNs could be an important potential factor in LPS-induced platelet aggregative dysfunction.
Catalase contributes to the prevention of platelet dysfunction during LPS-induced sepsis.
Key Words: catalase, lipopolysaccharide, platelet aggregation, polymorphonuclear 
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(Kaohsiung J Med Sci 2010;26:584–92)
Lipopolysaccharide (LPS) is derived from the outer
membrane of Gram-negative bacteria, and is one of
the major active components that stimulate a series of
inflammatory responses during infection, which initi-
ates septic syndrome, multiple organ dysfunction and
systemic failure [1–3]. In the course of this, coagulation
activation that leads to disseminated intravascular
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coagulation (DIC) could be regarded as an important
factor in promoting multiple organ failure. DIC is a
systemic thrombotic–hemorrhagic disorder that leads
to microvascular failure by obstructing the blood sup-
ply in various organs [4–6]. After the development of
pathogenic cascades, hemorrhage is the most frequent
and common presentation in DIC [7,8]. Coagulation
abnormalities and thrombocytopenia are commonly
observed in severe sepsis. Platelets could be consid-
ered to be closely associated with blood coagulation
failure. Bleeding patients with consumption coagu-
lopathy are most frequently treated with platelet
transfusions and various plasma products including
fresh frozen plasma and coagulation factor concen-
trates [9,10]. However, the effects are limited and the
mortality rate in severe sepsis remains high.
Platelets as key players in coagulation might have
been somewhat neglected with regard to these new
insights into the pathogenesis of coagulation abnormal-
ities in sepsis. Therefore, it is essential to understand
further the response of platelets during severe infection,
when we are searching for a better therapeutic interven-
tion. Platelets have a complex function in numerous
inflammatory and infective conditions, including sep-
sis; they are able to modulate not only their own func-
tion, but also that of other cells around them.
Platelets can combine with leukocytes to form
platelet–leukocyte aggregates [11]. Such an association is
regarded as an important initiating factor in the inflam-
matory cascade [12,13]. Activated leukocytes also can
influence platelet function. Levine et al have reported
that phagocytosis of granulocytes exerts a marked
inhibitory effect on platelet function. The granulocytes
could release factors that are capable of crossing a dialy-
sis membrane and inhibiting platelet aggregation [14].
Furthermore, polymorphonuclear leukocytes (PMNs)
can exert an antithrombotic influence by inhibition of
platelet activation [15–17]. Therefore, to clarify the role
of leukocytes in modulating platelet function during
sepsis, it is helpful to explore new avenues in bleeding
diathesis of septicemic and endotoxemic patients.
The aim of the present study was to investigate
the effect of interaction of platelets with leukocytes,
especially PMNs, on LPS-treated platelet aggregative
response and the possible effects of antioxidants. We
dealt with two questions. First, could leukocytes influ-
ence platelet function in sepsis? Second, could such
an interaction be mediated, at least in part, by leuko-
cyte production of hydrogen peroxide and nitric oxide?
METHODS
Materials
ADP, catalase, Escherichia-coli-derived LPS, NG-nitro-
L-arginine methyl ester (L-NAME), and pentobarbi-
tal were obtained from Sigma (St. Louis, MO, USA).
Animals
We adhered to the guidelines of the National Institutes
of Health for the use of experimental animals and all
experiments were approved by the Committee for
the Use of Experimental Animals of Kaohsiung Medical
University. Male Sprague–Dawley rats (350–400 g)
were purchased from the National Experimental
Animal Center (Nan-Kang, Taipei, Taiwan). The rats
were anesthetized by intraperitoneal injection of pen-
tobarbital (25 mg/kg). Blood samples were drawn
from the carotid artery.
Ex vivo experiments
Rats were injected through the femoral vein with either
LPS (5 mg/kg) or an equal volume of phosphate-
buffered saline for 90 minutes. Blood samples were
drawn from the carotid artery and collected into a
tube that contained sodium citrate (3.8%; 1 volume
for 9 volumes of blood).
In vitro experiments
The experimental conditions were divided into five
groups: (1) control: platelets from intact whole blood
(n = 12); (2) Platelet+LPS: platelets from intact whole
blood treated with LPS (final concentration 50 μg/mL
and 100μg/mL) for 30 minutes, 60 minutes and 90 min-
utes (n = 8 for each condition); (3) Platelet-WB + LPS:
platelets from whole blood treated with LPS for 
30 minutes, 60 minutes and 90 minutes (n = 10 for each
condition); (4) Platelet + PMN (3,500 cells/μL, n = 4);
(5) Platelet + LPS + PMN: LPS and PMNs (3,500 cells/
μL) from intact whole blood were added to intact
platelets during LPS treatment for 30 minutes, 60 min-
utes and 90 minutes (n = 4 for each condition). The
whole blood, platelets and PMNs were collected and
utilized within 2.5 hours.
Isolation of PMNs
Peripheral blood was obtained from the carotid
artery. Fresh heparinized blood was diluted 1:1 with
phosphate-buffered saline and layered over Ficoll-
Paque Plus solution (Amersham Biosciences Corp.,
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Piscataway, NJ, USA) and centrifuged at 1,500 rpm for
30 minutes at room temperature. The erythrocyte/
PMN-containing pellet was diluted 1:1 with normal
saline. Erythrocyte sedimentation was achieved by
diluting the suspension 1:10 with 6% dextran and
incubating for 30 minutes at 37°C. Red blood cells
were lysed with Tris–NH4Cl solution. PMNs were
collected and counted by an electronic counter.
Detection of platelet aggregation
Platelet-rich plasma (PRP) with a leukocyte count of
0–100/μL was prepared by centrifugation at 1,000 rpm
for 10 minutes at room temperature. Platelet-poor
plasma (PPP) was prepared by centrifugation at
3,000 rpm for 10 minutes. Platelet count was deter-
mined by an electronic counter (Sysmex microcell-
counter F-800; Toa Medical Electronics, Kobe, Japan).
The platelet count in the PRP was adjusted to
400,000/μL by dilution with PPP as needed [18].
Platelet aggregation in PRP was induced by 2.5 μM
ADP and measured with an aggregometer (PACKS-4
platelet aggregation chromogenic kinetic system;
Helena Laboratories, Beaumont, TX, USA). The tests
were performed at 37°C with 250 μL PRP in a silicon-
ized cuvette with continuous stirring. Catalase (25 U/
mL, 50 U/ml or 100 U/mL) and L-NAME (0.1 mg/mL
or 0.5mg/mL) were added to the reaction tube 90 min-
utes after incubation with platelets, PMNs and LPS.
Catalase and L-NAME were added to the reaction
tube 3 minutes before triggering with 2.5 μM ADP.
Statistical analysis
The data for platelet aggregation were presented as
percentage aggregation relative to PPP. Data were ex-
pressed as mean ± standard error of the mean. Signifi-
cance was determined by the t test and p < 0.05 was
considered to be statistically significant.
RESULTS
Catalase prevents ex vivo platelet
aggregative dysfunction in endotoxemic rats
Platelet aggregation was evaluated at 90 minutes after
treatment with 5 mg/kg LPS. ADP-induced aggrega-
tion was inhibited significantly in platelets derived
from endotoxemic rats compared with those derived
from control rats (Figure 1). Catalase, at a dose of 
at least 50 U/mL, contributed to the attenuation of
platelet hyporesponsiveness in endotoxemic rats, in a
dose-dependent manner.
Platelet aggregative dysfunction cannot be
induced directly in vitro by LPS
Platelets were isolated from normal whole blood of
rats. The effects of LPS on platelet aggregation were
detected in vitro (Figure 2). The platelet aggregative
responses of 50 μg/mL LPS were 65.8 ± 7.6%, 69.0 ±
9.6% and 67.9±11.8% after 30 minutes, 60 minutes and
90 minutes incubation, respectively. The platelet aggre-
gative responses of 100 μg/mL LPS were 71.4 ± 10.3%,
69.3 ± 9.8% and 68.6 ± 10.3% after 30 minutes, 60 min-
utes and 90 minutes incubation, respectively. There
were no differences between the experimental and
control groups. LPS by itself did not lead to platelet
aggregative dysfunction within 90 minutes.
LPS-induced aggregative inhibition on
platelets isolated from LPS-treated whole
blood
Whole blood was derived from normal rats and treated
with 100 μg/mL LPS for 30 minutes, 60 minutes and
90 minutes. Platelets were isolated from normal and
LPS-treated whole blood and platelet aggregation was
determined. LPS did not inhibit aggregation of plate-
lets isolated from normal whole blood. Aggregation
Figure 1. Effect of catalase on platelet aggregation ex vivo. Platelets
were isolated from rats with lipopolysaccharide (LPS)-induced endo-
toxemia (n=4). *p<0.05, **p<0.01 versus LPS, ***p<0.001.
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of platelets from whole blood treated with LPS for 
30 minutes and 60 minutes was unaffected. However,
platelet aggregation was significantly decreased to
37.5 ± 11.4% (n = 8) at 90 minutes after treatment with
LPS (Figure 3). The platelet aggregative response to
ADP was significantly inhibited when platelets were
isolated from LPS-treated whole blood.
Catalase prevents LPS-induced inhibition
of platelet aggregation from LPS-treated
whole blood
Platelets were isolated from normal and LPS-treated
whole blood. LPS-induced inhibition of aggregation
was detected in platelets isolated from LPS-treated-
whole blood (37.5 ± 11.4%) and the effect was signifi-
cantly attenuated (67.5 ± 5.9%) by 100 U/mL catalase
(Figure 4). Catalase by itself did not affect platelet
aggregation.
LPS-induced inhibition of platelet
aggregation is associated with PMNs
PMNs and platelets were isolated from normal whole
blood of rats. To clarify the influence of PMNs on
platelet function during LPS-induced endotoxemic
sepsis, PMNs were added to the platelet aggregative
reactions (Figure 5). Addition of PMNs alone did not
affect platelet aggregation (69.6 ± 4.8%). However,
when the PMNs were added, platelet aggregation was
inhibited to 40.5 ± 6.4% (n = 4) in the platelets contain-
ing 100 μg/mL LPS. PMNs might contribute to LPS-
induced platelet aggregative inhibition at 90 minutes
after platelets co-mixing with PMNs and LPS.
Figure 2. The timing and dose effect of lipopolysaccharide (LPS)
on platelet aggregation in vitro. Various doses of LPS (50mg/mL
and 100mg/mL) were utilized and incubated with platelets for 
30 minutes, 60 minutes and 90 minutes (n = 10).
Figure 3. Aggregative ability of platelets isolated from lipopolysac-
charide (LPS)-treated whole blood. LPS (100mg/mL) was added
to whole blood for 30 minutes, 60 minutes and 90 minutes
(n = 8). Control: platelets from intact whole blood. Platelet + LPS:
platelets from intact whole blood treated with LPS. Platelet-
WB+LPS: platelets from LPS-pretreated whole blood. ***p<0.001.
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Figure 4. Catalase on aggregative response of platelets isolated
from lipopolysaccharide (LPS)-treated whole blood. LPS
(100mg/mL) was added to whole blood for 90 minutes (n = 8).
PBS: volume control. Catalase: catalase-treated group. Control:
platelets from intact whole blood. Platelet + LPS: platelets from
intact whole blood treated with LPS. Platelet-WB + LPS:
platelets from LPS-pretreated whole blood. **p < 0.01.
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Effect of L-NAME on platelet aggregative
inhibition induced by LPS-treated PMNs
Different doses of L-NAME were added to platelets,
PMNs and LPS. Platelet aggregative inhibition
induced by LPS treatment and PMNs was not im-
proved by the addition of 0.1 mg/mL and 0.5 mg/mL
L-NAME (31.6 ± 10.2% and 25 ± 1.3%, respectively)
(Figure 6).
Synergistic effect of L-NAME and catalase
in preventing platelet aggregation
inhibition induced by LPS-treated PMNs
When catalase and L-NAME were applied separately at
a dose of 25 U/mL and 0.1 mg/mL, respectively, they
had no effect on LPS-induced inhibition of platelet
aggregation in the presence of PMNs. However, when
catalase and L-NAME were applied concomitantly,
they synergistically prevented inhibition of platelet
aggregation (58.7 ± 4.5%) (Figure 7).
DISCUSSION
The present study showed that ADP-induced aggre-
gation of platelets from endotoxemic rats was signifi-
cantly inhibited ex vivo. LPS was considered to be a
crucial factor for induction of hyporesponsiveness of
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Figure 5. Effect of polymorphonuclear leukocytes (PMNs) on
LPS-induced platelet aggregative inhibition. Platelets from
intact whole blood were collected (n = 4). The PMNs (3,500
cells/mL) were contained during LPS treatment for 90 minutes.
***p < 0.001 versus controls.
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Figure 6. Effect of NG-nitro-L-arginine methyl ester (L-NAME)
on lipopolysaccharide (LPS)-induced platelet aggregative inhibi-
tion. L-NAME was added to the incubation tube at 90 minutes
after platelets, polymorphonuclear leukocytes and LPS (n = 4).
**p < 0.01.
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Figure 7. Effect of NG-nitro-L-arginine methyl ester (L-NAME)
and catalase on LPS-induced platelet aggregative inhibition. 
L-NAME and catalase were added to the incubation tube at 90
minutes after platelets, polymorphonuclear leukocytes and LPS
(n = 4). **p < 0.01.
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platelet aggregation. LPS-induced aggregative hypo-
responsiveness was undetectable on intact platelets.
The platelets contained in whole blood and mixed
with PMNs were more susceptible to LPS treatment
than platelets alone. LPS-induced inhibition of platelet
aggregation ex vivo and in vitro was significantly
blocked by catalase. We conclude that LPS-activated
PMNs could influence platelet function through reac-
tive oxygen species (ROS) during LPS treatment.
Coagulation abnormalities and thrombocytopenia
are common features in severe sepsis. Decreased
platelet count could be regarded as a pivotal factor in
the pathogenesis of sepsis [9,19]. However, although
the functions of platelets in sepsis have been deter-
mined, they have yielded conflicting results. The
aggregability of platelets is consistently decreased in
septic patients compared with controls, regardless of
platelet count, thrombin generation, and overt DIC
status. The severity of sepsis is correlated with defec-
tive platelet aggregation [20]. However, contradictory
opinions have been stated. Gawaz et al noted the tim-
ing of the increased platelet aggregability in patients
[21]. Platelet aggregability is markedly increased in
patients with a complicated septic course, but is de-
creased over time in patients who develop sepsis. The
effects of bacterial products on platelet function vary
according to the species, timing of the study, and 
sepsis pathogenesis [22]. Thirty-five minutes after a
rabbit received endotoxin (100 μg/kg intravenously),
in vivo microscopy of the microcirculation discovered
massive aggregations of platelets and adhesion of
leukocytes in a precapillary that showed pre-stasis [23].
By 1 hour, numerous granulocytes were firmly adhered
to the endothelium and paved the venular endothelial
lining. Erythrocytes and platelets also adhered to the
granulocytes to form mixed thrombi, and platelet ag-
gregates and microthrombi were also seen at that time.
The granulocytes released some of their granules and
began to undergo diapedesis through the injured blood
vessel walls. The leukocytes could have been followed
by extravasation of erythrocytes and the appearance
of massive micro-hemorrhages [23]. The present study
proved that the platelet aggregability induced by ADP
was inhibited when platelets were isolated from en-
dotoxemic rats 90 minutes after LPS administration.
Endotoxemia-induced downregulation of platelet
aggregability can be prevented by catalase in a dose-
dependent manner [18]. Oxidative stress during endo-
toxemia can also participate in modulation of platelet
function. LPS induces the accumulation of ROS, es-
pecially hydrogen peroxide, in plasma during en-
dotoxemia, and might contribute to reduction of
ADP-induced platelet aggregability from endotox-
emic rats ex vivo [18].
Moreover, the hemostatic function of platelets can
be influenced, and coagulation abnormalities and
thrombocytopenia are common in severe sepsis [20].
The direct effects of LPS in modulating platelet func-
tion need to be clarified. Despite toll-like receptors
(TLRs) being activated on platelets and appearing to
be responsible for mediating LPS-induced thrombocy-
topenia in vivo [24,25], platelet aggregability cannot be
influenced directly by LPS in vitro. A previous study
showed LPS led to platelet hyporesponsiveness to
ADP only in the presence of endotoxemic plasma.
Intermediated mediators secreted in plasma are nec-
essary for LPS-induced platelet hyporesponsiveness
[18]. The aggregability of platelets isolated from whole
blood pre-treated with LPS was decreased. This find-
ing implies that an interaction between blood cells and
platelets is involved in sepsis. Moreover, our results
showed that the platelet aggregability was signifi-
cantly decreased when platelets were co-mixed with
PMNs and LPS concomitantly. LPS-activated PMNs
exerted a marked inhibitory effect on platelet aggre-
gability, whereas no significant inhibitory effect on
intact PMNs was seen. We consider that LPS-activated
PMNs contribute to the modulation of platelet aggre-
gability in sepsis.
PMNs are cardinal cellular effectors in the innate
host response to injury or infection. Besides partici-
pation in immune function, leukocytes, such as PMNs,
can also be activated by activated platelets and parti-
cipate in modulation of coagulation and interaction
with platelets during inflammatory diseases [11,12].
PMNs can also be activated by adhesive molecules,
primarily by P-selectin expressed on platelets. The
formation of PMN–platelet complexes enhances 
inflammation and pathogenesis [12,13]. Moreover,
phagocytosing granulocytes have been shown to
exert a marked inhibitory effect on platelet function.
Granulocytes can release factors that are capable of
crossing dialysis membranes and inhibiting platelet
aggregation [14]. The present study showed that
PMNs contributed to platelet hyporesponsiveness dur-
ing LPS treatment. The mediators, especially ROS, that
were secreted from PMNs were involved in stimulation
of platelet hyporesponsiveness during LPS treatment.
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PMNs express almost the entire repertoire of TLRs [26].
Among these, TLR4 can recognize the cell-wall con-
stituents of Gram-negative bacteria and is upregulated
in sepsis [26,27]. After TLR stimulation, the bactericidal
mechanisms in PMNs are initiated, and highly reac-
tive oxygen intermediates are produced and released
[28]. These intermediaries are highly reactive with
crucial biological molecules and can cause lipid per-
oxidation and irreversible protein structural modifi-
cations. Among these, hydrogen peroxide production
is important for platelet hyporesponsiveness during
endotoxemia. PMNs can be regarded as an important
source of hydrogen peroxide in plasma. Catalase, a
hydrogen peroxide scavenger, administered ex vivo and
in vitro prevents downregulation of platelet aggrega-
bility in response to ADP after LPS treatment.
Additionally, another PMN-derived factor for the
platelet inhibition that has been identified is nitric
oxide (NO) [15]. PMN-derived NO can directly inhibit
platelet activation by increasing platelet cGMP con-
tent [16]. LPS significantly increases nitrate production
within a 10-minute incubation period. LPS-induced
platelet aggregative inhibition is involved in the acti-
vation of a NO/cGMP pathway in platelets [29,30].
NO can react with superoxide to produce peroxynitrite.
Peroxynitrite inhibits aggregation of human platelets
stimulated by ADP (5μM), collagen, thrombin and
U46619, in a dose-dependent manner (50–200μM) [31].
Our previous study also has found that the amount
of plasma NO is higher than in the controls after
intravenous LPS injection [18]. However, L-NAME
and catalase were shown to have a synergistic effect in
in vitro LPS-induced septic study. Platelet hyporespon-
siveness to ADP was not attenuated when 20 mg/kg
L-NAME combined with 5 mg/kg LPS intravenous
injection into rats (16.4 ± 7.6%, LPS with L-NAME vs.
25.6 ± 5.5%, LPS; n = 6). We suggest that the synergis-
tic effect of L-NAME and catalase in preventing LPS-
induced platelet hyporesponsiveness is associated
with inhibition of peroxynitrite production. However,
the mechanism needs further investigation.
The experiments reported here are an attempt to
define a potential interaction between platelets and
leukocytes. PMNs can be used to understand LPS-
induced platelet aggregative dysfunction during endo-
toxemia. ROS, especially hydrogen peroxide, that are
derived from LPS-treated PMNs could be an important
contributing factor to LPS-induced platelet hypo-
responsiveness. Catalase contributes to the prevention
of platelet functional failure during LPS treatment.
The investigation of leukocyte–platelet association
offers a new approach for the therapy of sepsis.
In conclusion, the present study indicates that
PMNs can be used to help our understanding of LPS-
induced platelet aggregative dysfunction during
endotoxemia. The generation of ROS, especially hydro-
gen peroxide, from LPS-stimulated PMNs could be
an important factor in LPS-induced platelet aggrega-
tive dysfunction. Catalase contributes to the preven-
tion of platelet dysfunction during LPS-induced sepsis.
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導致敗血症最常見的致病菌是格蘭氏陰性桿菌，內毒素（endotoxin）是這些細菌細胞壁上
面的脂多醣（LPS）。敗血症會導致血液循環系統障礙，包含血小板去顆粒作用或瀰漫性血
管內凝血病變，當產生血管血栓或出血現象時，是導致敗血症的主要死亡原因。因為血液
中的白血球和所接觸的血小板無論在生理狀態或病理狀態下，彼此之間皆互有非常強烈的
互動關係。所以，在這個實驗中我們想要利用體外實驗來探究：內毒素所誘發的敗血症
中，進行吞噬作用的白血球和血小板凝集能力的相互關係。實驗中我們分別將內毒素置入
在富含血小板的血漿、全血以及富含血小板的血漿中加入白血球等三種不同樣品於 30 分
鐘、60 分鐘、90 分鐘由血小板凝集檢驗儀器測定血小板由 ADP刺激產生的凝集能力。體
外實驗研究結果中，我們發現內毒素（50 μg/mL、100 μg/mL）置入富含血小板的血漿後 
30、60、90 分鐘後均不會影響老鼠血小板的凝集功能反應，然而將內毒素分別置入全血及
富含血小板的血漿加入白血球 90 分鐘後，卻發現老鼠的血小板的凝集功能反應有顯著下降
的現象。然而，當單獨外加一氧化氮合成酶抑制劑 L-NAME並無法改善敗血症血小板凝集
功能下降的現象；但是，當外加過氧化氫酶 Catalase時，發現可以顯著改善敗血症血小板
凝集功能下降的現象。而且，當一氧化氮合成酶抑制劑 L-NAME合併過氧化氫酶 Catalase
一起作用時，發現可以改善敗血症血小板凝集功能下降的現象更為顯著。由這些研究結果
中指出：白血球對敗血症血小板凝集功能下降的現象中扮演一個很重要的角色，白血球影
響敗血症血小板凝集功能下降的主要機制很可能是經由活化的白血球所釋放至血漿的過氧
化氫（H2O2）的作用和過氧化氫影響一氧化氮（NO）的作用。總結：由此實驗發現在敗
血症中白血球和血小板有更進一步的互動關係，而且白血球、血小板間的相互關係，可以
藉由氧化自由基中過氧化氫的量來調節。
關鍵詞：過氧化氫酶，內毒素，血小板凝集，一氧化氮合成酶抑制劑，敗血症 
（高雄醫誌 2010;26:584–92）
